<DOC>
	<DOCNO>NCT00814385</DOCNO>
	<brief_summary>This study focus pre-pandemic prim man H5 influenza goal mount robust antibody response small quantity vaccine either H5 pandemic .</brief_summary>
	<brief_title>Immunogenicity Adjuvanted Non-adjuvanted H5N1 Booster Vaccine Adults Primed A/VN/1194/04</brief_title>
	<detailed_description>OBJECTIVES : Immunogenicity objectives 1 . To evaluate magnitude antibody responses one two 'priming ' 0.5mL intramuscular ( IM ) dose MF59-adjuvanted A/Vietnam/1194/2004 ( H5N1 Clade 1 ) influenza vaccine , dose contain 7.5μg H5N1 haemagglutinin , immunologically naïve subject ; 2 . To examine kinetics antibody responses one 0.5mL 'booster ' intramuscular dose antigenically drifted MF59-adjuvanted vaccine , non-adjuvanted antigenically drifted vaccine , give dos 3.75 7.5μg , subject prim one two dose MF59-adjuvanted A/Vietnam/1194/2004 ( H5N1 Clade 1 ) influenza vaccine ; 3 . To evaluate magnitude antibody responses one 0.5mL 'booster ' intramuscular dose antigenically drifted MF59-adjuvanted vaccine , non-adjuvanted antigenically drifted vaccine , give dos 3.75μg 7.5μg , subject prim one two dose MF59-adjuvanted A/Vietnam/1194/2004 ( H5N1 Clade 1 ) influenza vaccine ; 4 . To evaluate breadth antibody response induce 'priming ' ( see 1. , ) , 'booster ' vaccination regimen ( see 2. , 3. , ) , respect representative range antigenically distinct H5N1 virus ( wild-type attenuate ) ; 5 . To evaluate persistence antibody response induce 'priming ' ( see 1. , ) , 'booster ' vaccination regimen ( see 2. , 3. , ) . Safety objective 1 . To evaluate safety administration one two 'priming ' 0.5mL intramuscular ( IM ) dose MF59-adjuvanted A/Vietnam/1194/2004 ( H5N1 Clade 1 ) influenza vaccine ( dose contain 7.5μg H5N1 haemagglutinin ) , immunologically naïve subject , follow one 3.75μg 7.5μg 'booster ' dose antigenically drift MF59-adjuvanted H5N1 vaccine , non-adjuvanted antigenically drifted H5N1 vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subjects 18 59 year age , 60 year age old , mentally competent , sign informed consent form receive detailed explanation study protocol ; 2 . Are good health one stable ( See footnote ) medical condition , determine : 1 . Medical history , 2 . Physical examination , 3 . Clinical judgment medical investigator ; 3 . Are able understand comply study procedure complete study diary , contact , available study visit . 4 . Subjects experience fever ( defined axillary temperature &gt; 38oC ) within 3 day prior Visit 1 ; 5 . Subjects pregnant breastfeeding ; 6 . Females childbearing potential refuse use acceptable method birth control period 56 day vaccination . Adequate contraception define hormonal ( e.g. , oral , injection , transdermal patch , implant , cervical ring ) , barrier ( e.g. , condom spermicide diaphragm spermicide ) , intrauterine device ( e.g. , IUD ) , monogamous relationship vasectomise partner vasectomise 6 month prior subject 's study entry , abstain heterosexual intercourse ( e.g. , sexual orientation religious belief premarital intercourse ) ; 7 . Subjects serious disease , include : 1. cancer , 2. acute progressive hepatic disease , 3. acute progressive renal disease , 4. chronic pulmonary disease require home oxygen therapy , 5. active neurological disorder , 6. autoimmune disease ( include rheumatoid arthritis ) ; 8 . Subjects surgery plan study period ; 9 . Subjects bleed diathesis ; 10 . Subjects hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin kanamycin , component study vaccine ; 11 . Subjects history neurological symptom sign , anaphylactic shock follow administration vaccine ; 12 . Subjects know suspected impairment/alteration immune function , example , result : 1. receipt oral immunosuppressive therapy ( e.g. , corticosteroid therapy cancer chemotherapy ) ( longterm , inhaled steroid asthma management acceptable ) , 2. receipt immunostimulants interferon , 3. receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 3 month prior Visits 1 ( Day 1 ) , 2 ( Day 22 ) , 5 ( Day 382 ) , plan full length study , 4. high risk develop immunocompromising disease ; 13 . Actual plan receipt another vaccine period 3 week 3 week vaccination Days 1 , 22 , 382 ; 14 . Subjects history ( current ) drug alcohol abuse ( 20g/day female ; 30g/day male ) investigator 's opinion would interfere safety subject evaluation study objective ; 15 . Subjects unable lead independent life either physically mentally ; 16 . Have participate previous study H5 avian influenza vaccine ; 17 . Have previously vaccinate vaccine contain MF59 similar adjuvant ; 18 . Subjects condition , , opinion Investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>